Save over 80% over US Piqray (called Pivitko in Europe by Novartis) manufactured in Europe:
Manufacturer of Pivikto:
Novartis Pharma Stein AG. Postfach Stein SWITZERLAND. Schaffhauserstrasse CH-4332 Stein. Switzerland
Information about Pivikto (Alpelisib)
Pivikto (Alpelisib) is an oral medication used primarily in cancer treatment. It is a selective phosphoinositide 3-kinase (PI3K) inhibitor that works by targeting a specific pathway involved in the growth and survival of certain cancer cells. The drug is often prescribed in combination with other therapies for more effective treatment outcomes.
Product Highlights
- Pivikto is indicated for the treatment of advanced or metastatic hormone receptor-positive, HER2-negative breast cancer in adult women and men who have a PIK3CA mutation.
- This mutation is found in a subset of breast cancer cases, and Alpelisib is particularly effective in patients whose cancer has this genetic change.
Key Ingredient
Key Benefits
- As a targeted therapy, Pivikto is more selective than traditional chemotherapy, which can affect both cancerous and healthy cells. This selectivity may result in fewer side effects.
- It is especially beneficial for patients whose cancer cells have a PIK3CA mutation, making it a valuable option for personalized treatment plans.
- When used in combination with Letrozole, it has been shown to increase progression-free survival in breast cancer patients.
- Pivikto is convenient for patients as it is taken orally, allowing for easier adherence to treatment compared to intravenous therapies.
Direction of Use
- Pivikto is typically administered as a 300 mg oral dose once daily, but the exact dosage and schedule may vary depending on the patient's condition and concurrent therapies.
- It can be taken with or without food, though it’s recommended to take it at the same time each day for consistency.
- Regular follow-up with the healthcare provider is essential to monitor for side effects, especially since the drug can interact with other treatments or conditions.
Safety Concerns
Side Effects: Common side effects of Pivikto may include:
- Diarrhea
- Rash
- Nausea and vomiting
- Fatigue
- Hyperglycemia (high blood sugar)
- Liver enzyme abnormalities
- Regular monitoring of blood sugar levels, liver function, and other health parameters is necessary while using Pivikto.
- Because it can weaken the immune system, there may be an increased risk of infections.
Avoid Pivikto (Alpelisib) If
- Pivikto should not be used during pregnancy as it may harm the unborn baby. It is also not recommended for breastfeeding women.
- If you have a known allergy to Alpelisib or any of its components, you should avoid this medication.
- Patients with severe liver or kidney dysfunction should not use Pivikto, as it may worsen their condition or lead to dangerous side effects.
- Since Alpelisib may increase blood sugar levels, it should be avoided in patients with poorly controlled diabetes.
